Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Acquisitions & Divestments: 2022-2024

Historic Change in Acquisitions & Divestments for Immuneering (IMRX) over the last 3 years, with Dec 2024 value amounting to $5.5 million.

  • Immuneering's Change in Acquisitions & Divestments fell 71.13% to $5.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $51.0 million, marking a year-over-year decrease of 2.52%. This contributed to the annual value of $31.9 million for FY2024, which is 38.95% down from last year.
  • Per Immuneering's latest filing, its Change in Acquisitions & Divestments stood at $5.5 million for Q4 2024, which was up 10.00% from $5.0 million recorded in Q2 2024.
  • Immuneering's Change in Acquisitions & Divestments' 5-year high stood at $32.3 million during Q2 2022, with a 5-year trough of $5.0 million in Q3 2023.
  • Over the past 3 years, Immuneering's median Change in Acquisitions & Divestments value was $19.1 million (recorded in 2023), while the average stood at $16.1 million.
  • As far as peak fluctuations go, Immuneering's Change in Acquisitions & Divestments slumped by 74.03% in 2023, and later climbed by 12.79% in 2024.
  • Immuneering's Change in Acquisitions & Divestments (Quarterly) stood at $20.6 million in 2022, then dropped by 7.52% to $19.1 million in 2023, then tumbled by 71.13% to $5.5 million in 2024.
  • Its Change in Acquisitions & Divestments was $5.5 million in Q4 2024, compared to $5.0 million in Q2 2024 and $21.4 million in Q1 2024.